COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison of OpeN VErsus RoboTic Partial Nephrectomy (CONVERT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04011891
Recruitment Status : Recruiting
First Posted : July 9, 2019
Last Update Posted : September 2, 2020
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
A prospective randomized controlled feasibility trial for patients undergoing partial nephrectomy for T1 renal masses at Princess Margaret. Participants will be randomized receive either open or robotic partial nephrectomy.

Condition or disease Intervention/treatment Phase
Renal Masses Procedure: Robotic Partial Nephrectomy Procedure: Open Partial Nephrectomy Not Applicable

Detailed Description:

This is an interventional, unblinded RCT where a total of 30 patients who have consented to undergo partial nephrectomy for a T1 renal mass under the care of a uro-oncologist at Princess Margaret Cancer Centre will be randomized 1:1 to one of two arms:

Arm A: Robotic Partial Nephrectomy Arm B: Open Partial Nephrectomy

Patients will complete all pre-admission testing as per standard of care, regardless of arm allocation. Creatinine and eGFR are measured routinely pre-operatively and these values will be used as a baseline for all patients. In addition to standard pre-admission testing, participants will complete the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) offered either on paper at the visit or online via an emailed link.

Following either open or robotic partial nephrectomy, participants will be followed as per standard of care. Generally, this includes follow-up at 4-6 weeks, 6 months, 12 months and then either every 6 months thereafter or yearly, depending on pathology. All clinical outcome measures for this study are routinely reported post-operatively and in the follow-up period for partial nephrectomy patients. Quality of life will be assessed at the 4-7 week and 6 month follow-up visits using the EORTC QLQ-C30 offered either on paper at the visit or online via an emailed link. Participants will also be asked to complete a Surgical Recovery/Flank Bulge questionnaire regarding their incision healing and recovery from surgery at the 6-month follow-up visit.

The primary objective of this study is to assess the feasibility of a full RCT comparing perioperative outcomes in patients undergoing robotic vs. open partial nephrectomy at the investigator's institution.

The secondary objective of the study is to compare pilot outcome measures addressing oncologic, functional, and health economics outcomes to assess whether a full RCT is worthwhile and feasible.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Comparison of OpeN VErsus RoboTic Partial Nephrectomy Trial - a Feasibility Randomized Controlled Trial
Actual Study Start Date : November 1, 2019
Estimated Primary Completion Date : November 1, 2021
Estimated Study Completion Date : November 1, 2021

Arm Intervention/treatment
Active Comparator: Robotic Partial Nephrectomy
Partial nephrectomy performed using the DaVinci robotic surgical system.
Procedure: Robotic Partial Nephrectomy
Robotic partial nephrectomy using da Vinci robot.

Active Comparator: Open Partial Nephrectomy
Partial nephrectomy performed using the open approach.
Procedure: Open Partial Nephrectomy
Standard open partial nephrectomy

Primary Outcome Measures :
  1. Recruitment Potential [ Time Frame: Study duration (2 years) ]
    Rate of accrual [participants per month]

  2. Suitability of secondary outcome measures [ Time Frame: Study duration (2 years) ]
    Assess the feasibility of collecting all secondary outcome data. To be assessed qualitatively by the study team and by calculating the proportion of patients with each data point completed.

  3. Resource Utilization - Operating Room/Robotic Studio Time Availability [ Time Frame: Study duration (2 years) ]
    Assess the capacity of accommodating surgical time for a full scale clinical trial. Measured by time from decision to treat to surgery date.

  4. Resource Utilization - Cost of Study Participation [ Time Frame: Study duration (2 years) ]
    To develop an accurate budget for a full trail, we are assessing the average cost of running the trial per patient, per arm. This calculation will include: cost of study coordinator time (number of hours x hourly wage), additional cost of robotic disposables, and cost of additional testing outside of standard of care.

Secondary Outcome Measures :
  1. Operative Time [ Time Frame: Duration of surgery ]
    Operative time in minutes

  2. Warm Ischemia Time [ Time Frame: Duration of surgery ]
    Measured in minutes from the time of application of first vascular clamp to removal of clamp

  3. Blood Loss [ Time Frame: Duration of surgery ]
    Estimated blood loss (mL), transfusion rates, use of hemostatic agents (which agents and how many used)

  4. Conversion rate to radical nephrectomy or open partial nephrectomy [ Time Frame: Duration of surgery ]
    Time in minutes from the start of robotic partial nephrectomy to the time decision was made to convert

  5. Length of Stay [ Time Frame: 1-7 days ]
    Calculated from day of admission to day of discharge

  6. Complication Rates [ Time Frame: Up to 6 months post-surgery ]
    Clavien-Dindo classification and need for/extent of re-intervention

  7. Renal Function [ Time Frame: Up to 6 months post-surgery ]
    Creatinine and eGFR measured pre-op, day 1 post-op, 4-7 weeks post-op, 6 months post-op

  8. Positive margin rate [ Time Frame: 1-3 weeks post-operatively ]
    Frequency of positive margins as reported in the final pathology report.

  9. Margin size [ Time Frame: 1-3 weeks post-operatively ]
    Distance from tumour to surgical margin (mm) as reported in final pathology report.

  10. Analgesic Requirements [ Time Frame: Up to 6 months post-operatively ]
    use of epidural, PCA, or oral analgesia

  11. Quality of Life: EORTC QLQ-C30 [ Time Frame: Up to 6 months post-operatively ]
    Measured using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) at 4-7 weeks and 6 months post-operatively

  12. Surgical Recovery/Flank Bulge [ Time Frame: 6 months from surgical date ]
    Surveyed at 6 months post-operatively

  13. Health Economics [ Time Frame: Study duration (2 years) ]
    Estimated overall cost of surgery for each arm (surgical supplies, length of stay, etc.) and cost of post-operative readmissions and ER visits

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Radiologically characterized T1 renal mass
  • Elected for partial nephrectomy surgery
  • Under the care of a uro-oncologist at Princess Margaret Cancer Centre
  • Willing to comply with follow-up protocol
  • Capable of providing informed consent

Exclusion Criteria:

  • Radiologically characterized tumours ≥ T1
  • Unfit for general anesthetic
  • Unsuitable for robotic surgery (determined by treating physician)
  • Unwilling to comply with standardized follow-up protocol
  • Evidence of metastatic disease
  • Solitary kidney
  • Previous surgery on affected kidney
  • Multiple tumours
  • Known genetic syndromes predisposing to multiple renal tumours (e.g., VHL, TS, BHD)
  • Pregnancy
  • Inability to read, understand, and complete the questionnaires written in English

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04011891

Layout table for location contacts
Contact: Robert Hamilton, MD 416-946-2909
Contact: Kopika Kuhathaas, BSc 416-946-2282

Layout table for location information
Canada, Ontario
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Robert Hamilton, MD    416-946-2909      
Sponsors and Collaborators
University Health Network, Toronto
Layout table for additonal information
Responsible Party: University Health Network, Toronto Identifier: NCT04011891    
Other Study ID Numbers: 18-5885
First Posted: July 9, 2019    Key Record Dates
Last Update Posted: September 2, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Health Network, Toronto:
Minimally Invasive Surgery
Robotic Surgery
Partial Nephrectomy